We sought to define whether intra-tumor genetic heterogeneity would be present between the primary breast cancer and the brain metastatic deposits, and whether the progression from HER2-positive primary breast cancer metastatic to the brain following anti-HER2 therapy was associated with shifts in clonal composition. Here, ERBB2 is linked to neoplasm.